Immunotherapy of cancer

被引:95
作者
Borghaei, Hossein [2 ]
Smith, Mitchell R. [2 ]
Campbell, Kerry S. [1 ]
机构
[1] Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
基金
美国国家卫生研究院;
关键词
Immunotherapy; Cancer; Monoclonal antibody; Cell-based therapy; Toll-like receptors; ANTI-CD20; MONOCLONAL-ANTIBODY; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; CHEMOTHERAPY PLUS RITUXIMAB; KIR LIGAND INCOMPATIBILITY; METASTATIC BREAST-CANCER; NATURAL-KILLER-CELLS; PHASE-II TRIAL; RANDOMIZED CONTROLLED-TRIAL;
D O I
10.1016/j.ejphar.2009.09.067
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 193 条
[1]
Advani R, 2006, BLOOD, V108, p209A
[2]
Antibody-dependent cellular cytotoxicity in HIV infections [J].
Ahmad, A ;
Menezes, J .
FASEB JOURNAL, 1996, 10 (02) :258-266
[3]
CD4+ T-regulatory cells:: toward therapy for human diseases [J].
Allan, Sarah E. ;
Broady, Raewyn ;
Gregori, Silvia ;
Himmel, Megan E. ;
Locke, Natasha ;
Roncarolo, Maria Grazia ;
Bacchetta, Rosa ;
Levings, Megan K. .
IMMUNOLOGICAL REVIEWS, 2008, 223 :391-421
[4]
Human NK cell education by inhibitory receptors for MHC class I [J].
Anfossi, Nicolas ;
Andre, Pascale ;
Guia, Sophie ;
Falk, Christine S. ;
Roetynck, Sophie ;
Stewart, C. Andrew ;
Breso, Violette ;
Frassati, Coralie ;
Reviron, Denis ;
Middleton, Derek ;
Romagne, Francois ;
Ugolini, Sophie ;
Vivier, Eric .
IMMUNITY, 2006, 25 (02) :331-342
[5]
[Anonymous], P AM SOC CLIN ONCOL
[6]
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma [J].
Ansell, Stephen M. ;
Horwitz, Steven M. ;
Engert, Andreas ;
Khan, Khuda Dad ;
Lin, Thomas ;
Strair, Roger ;
Keler, Tibor ;
Graziano, Robert ;
Blanset, Diann ;
Yellin, Michael ;
Fischkoff, Steven ;
Assad, Albert ;
Borchmann, Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2764-2769
[7]
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies [J].
Bartlett, Nancy L. ;
Younes, Anas ;
Carabasi, Matthew H. ;
Forero, Andres ;
Rosenblatt, Joseph D. ;
Leonard, John P. ;
Bernstein, Steven H. ;
Bociek, R. Gregory ;
Lorenz, Jennie M. ;
Hart, Bruce W. ;
Barton, Jeremy .
BLOOD, 2008, 111 (04) :1848-1854
[8]
Baselga J, 2001, EUR J CANCER, V37, pS16
[9]
Clinical trials of Herceptin® (trastuzumab) [J].
Baselga, J .
EUROPEAN JOURNAL OF CANCER, 2001, 37 :S18-S24
[10]
Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744